Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by Justdosomeddon Aug 10, 2022 3:27pm
115 Views
Post# 34886043

Positive Performance With Recent Study Results

Positive Performance With Recent Study Results
Algernon Pharmaceuticals is up another 11% today as the recently released results from the Ifenprodil IPF and Chronic Cough study continue to show signs of promise for both patients needing an effective treatment and investors looking to invest in the high-potential drug formulation. Focusing on just the IPF market, there are only 2 approved treatments for slowing the progression of IPF; pirfenidone and nintedanib. Due to the duopoly, these treatments can cost up to $100,000 per patient. And with around 30,000-40,000 new cases each year, there's a significant market of people who need lower-cost treatments.
 
https://medlineplus.gov/genetics/condition/idiopathic-pulmonary-fibrosis/
 
The statistically significant results coupled with the adjusted geometric cough means shows that $AGN.C’s approach of repurposing drugs to treat other diseases is beginning to pay off. For those who aren't too familiar, I've written the statistics below.
 
- The geometric mean 24-hour cough counts were reduced by 32.0% at 4 weeks (p = 0.023) and 39.5% at 12 weeks (p = 0.001) compared to baseline.
- The geometric mean awake cough counts were reduced by 30.2% at 4 weeks (p = 0.038) and 37.4% at 12 weeks (p = 0.002) compared to baseline.
- Of the 20 patients who enrolled, 13 (65%) had stable or improved FVC over the 12-week treatment period when compared to an anticipated placebo effect of 40% (statistically significant)
 
Overall, the current market cap still doesn't reflect the true value of the company. With both the market needing disruption and the company continuing to develop, there's a lot of upside potential left here.
 
<< Previous
Bullboard Posts
Next >>